

Haploinsufficiency of mTR results in defects in telomere elongation

Karen S. Hathcock^{*†}, Michael T. Hemann^{*†}, Kay Keyer Opperman[‡], Margaret A. Strong[‡], Carol W. Greider[‡], and Richard J. Hodes^{*§¶}

^{*}Experimental Immunology Branch, National Cancer Institute, and [§]National Institute on Aging, National Institutes of Health, Bethesda, MD 20892; and [‡]Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205

Edited by Mary-Lou Pardue, Massachusetts Institute of Technology, Cambridge, MA, and approved January 3, 2002 (received for review October 15, 2001)

Telomeres are usually maintained about an equilibrium length, and the set point for this equilibrium differs between species and between strains of a given species. To examine the requirement for telomerase in mediating establishment of a new telomere length equilibrium, we generated interspecies crosses with telomerase mTR knockout mice. In crosses between C57BL/6J (B6) and either of two unrelated mouse species, CAST/Ei and SPRET/Ei, telomerase mediated establishment of a new telomere length equilibrium in wild-type mTR^{+/+} mice. This new equilibrium was characterized by elongation of the short telomeres of CAST/Ei or SPRET/Ei origin. In contrast, mTR^{-/-} offspring of interspecies crosses failed to elongate telomeres. Unexpectedly, haploinsufficiency was observed in mTR^{+/-} heterozygous interspecies mice, which had an impaired ability to elongate short SPRET/Ei or CAST/Ei telomeres to the new equilibrium set point that was achieved in wild-type mTR^{+/+} mice. These results demonstrate that elongation of telomeres to a new telomere set point requires telomerase and indicate that telomerase RNA may be limiting *in vivo*.

Telomeres are DNA–protein complexes at the ends of linear eukaryotic chromosomes that play a critical role in maintaining chromosome stability. In mammalian cells, telomere DNA sequences consist of hundreds of tandem copies of the hexanucleotide repeat (TTAGGG)_n. The average telomere restriction fragment length ranges among species from 10 to 15 kb in human to >50 kb in some *Mus musculus* strains. In the absence of compensatory mechanisms, telomeres shorten with each cell division because of incomplete replication of lagging strand DNA (1, 2). Human cells, when their telomeres become critically short, lose the capacity to divide and enter into cellular senescence (3).

Telomerase is a unique RNA-dependent DNA polymerase that synthesizes telomeric sequence repeats (4). Telomere elongation by telomerase compensates for telomere loss that occurs with cell division. Thus, telomere length is maintained as an equilibrium between processes that shorten and those that lengthen telomeres. This equilibrium is maintained around a specific “set point” that is species, and often strain, specific (1, 2). Regulation of this set point involves a number of different genes (5–8). Telomere binding proteins play a key role in regulating the set point, and alteration in the amount of telomere protein bound to telomeres can alter the set point (9–11). In the absence of telomerase, telomere length can no longer be maintained at the established set point.

Telomerase contains two essential components, the catalytic protein component (telomerase reverse transcriptase or TERT) and an RNA component (telomerase RNA or TR) that provides the template for telomere synthesis (1, 2). The physiologic role for telomerase has been demonstrated by studies in which one of the telomerase components is genetically inactivated and the consequences analyzed. Mice in which the RNA component mTR is deleted lack telomerase activity and initially show no detectable phenotypic change (12). However, after multiple generations of breeding, homozygous mTR^{-/-} mice have significantly shortened telomeres and show increased frequency of

chromosomal fusions (13). Apoptosis is the predominant cellular consequence of short telomeres in these mice. Germ cell apoptosis is seen in fourth generation mTR-deficient (G4) mice and increases in severity up to the sixth generation, which is functionally infertile (13, 14). Increased apoptosis is also seen in *in vitro* activated leukocytes from late generation mice (13).

Crosses between the mouse species *Mus musculus domesticus*, which has long telomeres (≈50 kb) and SPRET/Ei, which has shorter telomeres (10–15 kb), result in significant elongation of the short SPRET/Ei telomeres (7). Segregation analysis showed that a recessive gene on distal chromosome 2, unlinked to genes encoding known telomerase or telomere-associated components, plays a role in telomere elongation. These findings demonstrated that telomere lengthening can occur during normal development.

To analyze the mechanism mediating telomere elongation, we examined whether telomerase is required for elongation of short telomeres in crosses between *M. musculus domesticus* strain C57BL/6 (B6) and either of two short-telomere mice, *Mus spretus* (SPRET/Ei) or *Mus musculus castaneus* (CAST/Ei). We found that the increases in telomere length that occur in these crosses are mediated by telomerase. Unexpectedly, heterozygous mTR^{+/-} mice were impaired in the ability to increase telomere length, suggesting that limiting telomerase may result in haploinsufficiency. Recent evidence suggests that hTR haploinsufficiency may be a cause of the human disease autosomal dyskeratosis congenita (15). Our results support the conclusion that a deficiency in telomerase RNA can lead to a deficiency in telomere elongation.

Methods

Mice. *M. musculus domesticus* C57BL/6(B6), *M. spretus* (SPRET/Ei), and *M. Musculus castaneus* (CAST/Ei) mice were obtained from The Jackson Laboratory. These strains and crosses were bred at Bioqual (Rockville, MD) and at The Johns Hopkins School of Medicine (Baltimore). mTR-deficient mice were derived as previously described (12) and maintained as mTR heterozygotes on a B6 background (B6.mTR). mTR genotypes (wild type, +/+; heterozygous, +/-; or deficient, -/-) were identified with tail DNA purified by using a Dneasy tissue kit (Qiagen, Chatsworth, CA) and a three-primer PCR system. PCR reactions were run on a GeneAmp PCR machine

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: TERT, telomerase reverse transcriptase; TR, telomerase RNA component; TRF, telomere restriction fragment; Q-FISH, quantitative fluorescence *in situ* hybridization; TRAP, telomeric repeat amplification protocol; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Data deposition: The sequences reported in this paper have been deposited in the GenBank database [accession nos. AY058901 (SPRET/Ei mTR) and AY058900 (CAST/Ei mTR)].

[†]K.S.H. and M.T.H. contributed equally to this work.

[¶]To whom reprint requests should be addressed. E-mail: richard_hodes@nih.gov.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

(Perkin–Elmer) by using the following cycling conditions: 95°C, 10 min; 94°C, 1 min; 63°C, 1 min; 72°C, 1 min (40×); and 72°C, 10 min. Reactions were carried out in PCR buffer containing 1.5 mM MgCl₂ (Perkin–Elmer), 0.2 mM dNTPs, 0.5 unit of *Taq* Gold polymerase (Perkin–Elmer), 2 μl of purified tail DNA, and three primers [wild-type forward (5′-agtgtctcggtccttact-3′), 1 μM; knock-out forward (5′-taccgtggatgtggaatg-3′), 0.25 μM; and reverse (5′-gtgatgttgagttcccacag-3′), 1 μM]. Wild-type genomic mTR DNA is identifiable as a 367-nt band and KO mTR DNA as a 196-nt band; mTR heterozygous DNA yields both bands. Experiments were performed by using 3–8-month-old mice.

Pulsed-Field Gel. DNA plugs were made from liver or spleen cells, enzyme digested, and subjected to pulsed-field gel electrophoresis as previously reported (7, 16).

In-Gel Hybridization. Following electrophoresis and ethidium bromide staining, gels were dried on filter paper for 1 h at 50°C. Gels were prehybridized for 1 h at 55°C in 20 mM NaH₂PO₄/0.1% SDS/5 × Denhardt's Reagent/5 × SSC and hybridized with probe for 3 h at 55°C in 5 ml of prehybridization solution. (CCCTAA)₄ oligonucleotides were obtained from Operon Technologies (Alameda, CA). Oligonucleotides were end-labeled with [γ -³²P]ATP and then purified by using NAP-5 columns (Pharmacia Biotech). After hybridization, gels were washed three times for 20 min in 3 × SSC at room temperature and three times for 20 min in 3 × SSC/0.1% SDS at 58°C. Images were acquired with a Fuji Film BAS 1500 bioimaging analysis system with IMAGE READER software (version 1.3E).

Quantitative Fluorescence *in Situ* Hybridization (Q-FISH). Spleen cells were stimulated *in vitro* for 48 h with Con A, lipopolysaccharide, and rIL2; 10 μg/ml Colcimide was added during the last 30 min of culture. Arrested cells were centrifuged for 10 min at 300 × g, resuspended in 0.4% KCl, and swelled for 4 min at 37°C. After hypotonic treatment, an equal volume of 3:1 methanol:acetic acid was added to each tube. Cells were then pelleted and washed in fresh fixative at least four times before by using. Cells were dropped onto clean glass slides to generate metaphase spreads. PNA FISH was performed with a Cy3-labeled (CCCTAA)₃ PNA oligonucleotide (PE Biosystems) as described (17), and chromosomes were counterstained with DAPI (Sigma). FluoreSphere fluorescent beads (Molecular Probes) were used to monitor signal intensity loss during microscope use. Signal intensities were calculated by using designated Q-FISH software provided by the Lansdorp laboratory (17). Telomere signal intensities were measured on at least 10 metaphases for each mouse.

Telomerase Activity. Telomerase was measured with an Invitrogen kit and a nonradioactive PCR-based telomeric repeat amplification protocol (TRAP) modified from the procedure originally described by Kim *et al.* (18). *In vitro* activation conditions for induction of telomerase activity in lymphocytes have been described previously (19). Briefly, single cell suspensions of spleen mononuclear cells were isolated from age-matched (B6.mTR^{+/-} × SPRET/Ei) × B6.mTR^{+/-} mice that were genotypically mTR^{+/+}, mTR^{+/-}, or mTR^{-/-}. Three × 10⁶ cells/ml were activated with a mixture of CD3-specific mAb (2C11) (5 μg/ml), lipopolysaccharide (10 μg/ml), and IL-2 (20 units/ml). After 60 h of culture, cells were harvested, counted, and lysed in Chaps buffer. Cell lysates were serially diluted and examined for telomerase activity. A portion of each lysate was heated to 85°C to inactivate telomerase and was included as a control in each assay. Reaction products were resolved on 10% acrylamide gels, stained with SyberGreen (Molecular Probes), and detected with a PhosphorImager (Molecular Dynamics).

RNA Isolation. RNA was isolated from testes of individual 3–6-month-old mice by using an Rneasy kit (Qiagen) for (B6 × SPRET/Ei) crosses or with TriZol reagent (Life Technologies, Grand Island, NY) for (B6 × CAST/Ei) crosses. After isolation, RNA was treated with Rnase-free DNase (Promega), phenol:chloroform extracted, precipitated, and resuspended in 10 mM Tris/0.5 mM EDTA (pH 8). RNA concentrations were determined by OD₂₆₀ with a GeneSpec1 spectrophotometer (Hitachi, Tokyo). RNA integrity was confirmed by running a small RNA sample from each mouse on a 2% agarose gel, and RNA was visualized with ethidium bromide.

Real-Time PCR. Real-time PCR was performed with the Taqman Gold kit (Applied Biosystems) and a two-step reaction. Primers used for reverse transcription and PCR include mTR-24F 5′-tgtgggttctgtctttttgttctcgcg-3′, mTR-134R 5′-gtttttgaggctcgg-gaacgcg-3′, mTR-24F (SPRET) 5′-tgtgggttctgtctttttgttctcgcg-3′, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) F 5′-ttcaccaccatggagaaggc-3′, and GAPDH R 5′-ggcatggactgtggtcatga-3′ (20). Taqman probes were synthesized by Biosearch Technologies and included mTR 51T 5′-FAM-ccgctgttttctcgcg-gacttcacgcg-BHQ-1-3′ and mGAPDH 5′-ROX-tgcactctgcaccac-caactgcttag-BHQ-2-3′.

To synthesize cDNA, 50 ng to 2.5 μg of total RNA was mixed with 300 nM each of mTR-134R and GAPDH R in a 50-μl reaction, heated for 5 min at 80°C, and chilled on ice. A 20-μl RT reaction contained 10 μl of RNA/primer, 0.25 unit of multi-scribe reverse transcriptase, 0.2 unit of Rnase inhibitor, 1 × RT buffer, 5.5 mM MgCl₂, and 2 mM dNTPs. Reactions were incubated for 50 min at 48°C, RT heat-inactivated at 85°C for 5 min, and cDNA either used immediately for PCR or stored at –20°C. Initially, genomic DNA contamination was assessed for each sample by using a control in which no RT was added (–RT). All RNA samples were found not to have significant DNA contamination as fluorescent intensities for GAPDH and mTR in –RT controls were not above background levels.

Each PCR reaction contained 1 × *Taq* Gold buffer (no ROX dye)/5.5 mM MgCl₂/1 mM dNTPS/600 nM each of mTR and GAPDH primers/200 nM mTR probe/1.2 μM GAPDH probe, 0.5 unit of *Taq* Gold polymerase/5 μl of cDNA. PCR reactions were run on a Smart Cycler (Cepheid) with the following cycling conditions: 95°C, 10 min; 95°C, 15 s; 55°C, 30 s; 72°C, 45 s (40×); 72°C, 3 min. PCR products were initially run on agarose gels to confirm equimolar ratios of mTR and GAPDH products. Cycle thresholds were determined by using the second derivative of each curve for each dye channel. GAPDH was used as a loading control to monitor RT efficiency and RNA amount. Only samples that had similar and reproducible GAPDH thresholds (±0.5 cycles) for each input RNA concentration were used for quantitative purposes.

For quantitation, SPRET/Ei and CAST/Ei wild-type RNA was diluted to 500, 250, 100, and 50 ng/RT reaction. cDNA generated from these reactions was used to create a standard curve by using the input RNA concentration from the RT reaction and the threshold cycle from PCR. Slopes from respective standard curves were used to determine RNA concentrations from mTR^{+/+} and mTR^{+/-} crosses by using the cycle threshold. Each RT reaction was repeated at least two independent times, and PCR reactions were repeated a minimum of four times.

Telomerase RNA Sequencing. PCR amplification of telomerase RNA sequences was performed with primers mTR-pF 5′-GTGGGAAGTGCACCCGGAAGTCTCGGTTTC-3′ and mTR-pR 5′-CCCAGAAGTCCGACAGTTCTAGCGGC-3′ for 35 cycles of 95°C, 15 s; 60°C, 1 min; 72°C, 1 min. PCR products from two B6, two SPRET/Ei, and two CAST/Ei mice were sequenced.




Fig. 1. CAST/Ei telomeres are elongated in offspring of a CAST/Ei \times B6 cross. Telomere restriction fragments (TRF) from a B6, a CAST/Ei, and a (B6 \times CAST/Ei) F1 mouse are shown. (A) End-labeled (CCCTAA)₃ probe was used in in-gel hybridization to *DpnII* digests of agarose-embedded genomic DNA. The boxed region represents the shortest telomeres where differences in the distributions are most evident. (B) Q-FISH analysis of B6, CAST/Ei, and (B6 \times CAST/Ei) F1 telomeres. Frequency distributions of 800 telomere signals from each mouse are shown.

Results

Establishment of a New Telomere Set Point Occurs in Interspecies Crosses. Some *M. musculus* mouse strains, such as B6, have characteristically long telomeres, with an average length of \approx 50 kb. In contrast, SPRET/Ei and CAST/Ei have shorter telomere length distributions (7, 15, 21, 22). As previously demonstrated (B6 \times SPRET/Ei), mice have a bimodal distribution of telomere length as assayed by pulsed field gel Southern analysis or Q-FISH (data not shown, ref. 7). The shorter set of telomeres, presumably of SPRET/Ei origin, is significantly longer in (B6 \times SPRET/Ei) mice than are telomeres from parental SPRET/Ei mice, indicating that significant telomere elongation occurred during normal development. No detectable elongation of longer, presumably B6, telomeres was observed, suggesting that elongation is restricted to the shortest telomeres. To determine whether telomere elongation in interspecies crosses is specific to SPRET/Ei or reflects a more general mechanism of telomere length regulation, we crossed B6 and CAST/Ei mice. Southern analysis of (B6 \times CAST/Ei) mice similarly demonstrated significant lengthening of the shorter CAST/Ei telomeres (Fig. 1A). The length of individual telomeres in parental and F1 mice was also assessed by Q-FISH, a technique that measures the amount of TTAGGG sequence in individual metaphase telomeres (17). In (B6 \times CAST/Ei) mice, lengthening of the shorter telomeres was seen (Fig. 1B). Lengthening of shorter telomeres in interspecies crosses thus seems to be a general phenomenon associated with establishment of new telomere set points.

Telomerase Is Required to Establish a New Length Equilibrium in Interspecies Crosses. To determine whether telomerase is required for telomere elongation in interspecies crosses, we crossed both SPRET/Ei and CAST/Ei to heterozygous mTR-deficient (mTR^{+/-}) B6 mice. Telomere length analysis of (B6 \times SPRET/Ei) F1 mice showed that in mTR^{+/+} F1 mice, the short telomeres were elongated as had been seen previously (Fig. 2A and C). It was anticipated that mTR heterozygous +/- mice would have intact telomerase activity and would therefore express wild-type telomere elongation. Unexpectedly, however,

heterozygous mTR^{+/-} (B6 \times SPRET/Ei) F1 mice exhibited an impaired ability to increase the length of SPRET/Ei telomeres (Fig. 2A and C).

We also crossed CAST/Ei with mTR^{+/-} B6 mice. Whereas all mTR^{+/+} offspring showed substantial elongation of the short telomere class, mTR^{+/-} offspring were deficient in elongation of these telomeres (Fig. 2B). This outcome was consistent independent of the male or female parental origin of the intact mTR allele in these crosses. These results indicate that telomere elongation in these crosses is mediated by telomerase. In addition, the lack of elongation to the new set point in mTR^{+/-} mice suggests that telomerase RNA may be limiting in mTR^{+/-} heterozygotes.

Telomere Shortening Is Seen in Telomerase Null Offspring from Interspecies Crosses. To further study the relationship between telomerase activity and telomere length, interspecies heterozygous mTR^{+/-} (B6 \times SPRET/Ei) and mTR^{+/-} (B6 \times CAST/Ei) mice were crossed with mTR^{+/+} B6 mice, generating animals that were mTR wild-type (+/+), heterozygous (+/-), or homozygous-deficient (-/-). In mTR wild-type (+/+) [(B6 \times SPRET/Ei) \times B6] mice, a distribution of telomere lengths comparable to that seen in mTR wild-type (B6 \times SPRET/Ei) mice was seen by pulsed field gel analysis (Fig. 3A). In mTR heterozygous (+/-) [(B6 \times SPRET/Ei) \times B6] mice, the shortest telomeres were maintained at a length similar to that observed in parental SPRET/Ei. Thus, there was a deficiency in elongation of these telomeres that was similar to the deficiency seen in the initial mTR^{+/-} (B6 \times SPRET/Ei) mice. Telomere length profiles in homozygous mTR-deficient (-/-) [(B6 \times SPRET/Ei) \times B6] mice showed telomere shortening such that the shortest telomeres in these mice were shorter than those of the SPRET/Ei parent, as seen in the boxed area of Fig. 3A. Q-FISH analysis of telomeres from these mice showed a bimodal distribution of telomere lengths (Fig. 3C). mTR^{+/+} [(B6 \times SPRET/Ei) \times B6] mice had no telomeres in the shortest telomere class of 1–2 Telomere fluorescence units, whereas mTR^{+/-} mice had more telomeres in this short range. Finally, mTR^{-/-} [(B6 \times SPRET/Ei) \times B6] mice showed a substantial number of telomeres in the shortest telomere class (Fig. 3C).

Analogous experiments were carried out with CAST/Ei mice. mTR^{+/-} (B6 \times CAST/Ei) F1 mice were crossed to B6 mTR^{+/-} mice. Again, the smallest visible telomeres were shorter in mTR^{-/-} offspring than in mTR^{+/-} littermates (Fig. 3B). The fact that telomeres in mTR^{-/-} interspecies mice were shorter than telomeres from mTR^{+/-} littermates suggests that some addition of telomere repeats occurs in mTR^{+/-} animals. In addition, no chromosome fusions were seen in either mTR^{+/-} or mTR^{-/-} mice (data not shown), suggesting that telomere function was not compromised by limiting telomerase. Thus, regulation of telomere length represented by elongation to the new (B6 \times SPRET/Ei) or (B6 \times CAST/Ei) set point can be separated from maintenance of minimal telomere function.

mTR^{+/-} Heterozygotes Have Reduced Telomerase RNA. To determine whether the impaired lengthening of telomeres in mTR^{+/-} mice was because of reduced telomerase activity, enzymatic activity was measured by *in vitro* TRAP assay. Telomerase activity was detected in lysates of activated splenocytes from [(B6 mTR^{+/-} \times SPRET/Ei) \times B6 mTR^{+/-}] mice that were mTR^{+/+} or mTR^{+/-}, but was undetectable in mTR^{-/-} cells (Fig. 4). The TRAP assay showed no difference between telomerase activity levels in mTR^{+/+} and mTR^{+/-} cells. However, this assay may not be sufficiently quantitative to detect small differences in telomerase activity. Thus, to examine whether telomerase RNA might be limiting in mTR^{+/-} mice, we measured mTR levels by using quantitative real-time PCR. Total testis RNA from wild-type CAST/Ei was used to generate a standard curve. RNA was then




Fig. 2. Elongation of short telomeres is impaired in $mTR^{+/-}$ offspring of B6 $mTR^{+/-}$ \times SPRET/Ei and B6 $mTR^{+/-}$ \times CAST/Ei crosses. (A) TRF distributions from the B6 $mTR^{+/-}$ and SPRET/Ei parents and $mTR^{+/+}$ and $mTR^{+/-}$ offspring of a B6 $mTR^{+/-}$ \times SPRET/Ei cross. End-labeled (CCCTAA)₃ probe was used in in-gel hybridization to *DpnII* digests of agarose-embedded genomic DNA. The boxed region represents the shortest telomeres where differences in the distributions are most evident. (B) TRF distributions from the B6 $mTR^{+/-}$ and CAST/Ei parents and $mTR^{+/+}$ and $mTR^{+/-}$ offspring of a B6 $mTR^{+/-}$ \times CAST/Ei cross. (C) Q-FISH analysis of B6 $mTR^{+/-}$, SPRET/Ei, and (B6 \times SPRET/Ei) $mTR^{+/+}$ and $mTR^{+/-}$ telomeres. Frequency distributions of 1,600 telomere signals from two mice of each genotype are shown.

isolated from three independent (B6 \times CAST/Ei) $mTR^{+/+}$ and $mTR^{+/-}$ littermates, and similar amounts of RNA were subjected to quantitative real-time PCR analysis. To control for the amount of RNA in each sample, a portion of the mouse GAPDH gene was amplified and showed similar PCR signal in all samples tested (Fig. 5). The level of RNA in $mTR^{+/-}$ samples was reproducibly less than half of that from $mTR^{+/+}$ littermates (Fig. 5). Similar experiments were carried out with (B6 \times SPRET/Ei) $mTR^{+/+}$ and $mTR^{+/-}$ littermates, although the primers differed because of sequence variation in SPRET/Ei mTR (see below). The amount of mTR RNA in $mTR^{+/-}$ cells (81 ng) was again less than half that of $mTR^{+/+}$ mice (260 ng). Thus, the lower level of telomerase RNA in $mTR^{+/-}$ heterozygotes may lead to the observed deficiency in telomere elongation *in vivo*.

Species-Specific Differences in Telomerase RNA Sequence Are Not Responsible for Loss of Telomere Elongation. In $mTR^{+/-}$ heterozygous (B6 \times SPRET/Ei) F1 or (B6 \times CAST/Ei) F1 mice, the single intact mTR gene is of SPRET/Ei or CAST/Ei origin, respectively. To examine whether potential sequence differences in mTR led to the deficiency in telomere lengthening, we sequenced mTR from B6, SPRET/Ei, and CAST/Ei. B6 and CAST/Ei mTR sequences were identical, whereas six sequence differences exist in the SPRET/Ei gene. These differences are C47/U, G80/A, G85/U, C154/U, C180/U, and C345/U. These changes are not in conserved regions of the telomerase RNA (23) and thus are not expected to lead to functional changes in

telomerase activity. Because the RNA sequence was identical in B6 and CAST/Ei, the deficiency in telomere elongation observed in (B6 \times CAST/Ei) F1 mice is not because of a defect in CAST/Ei mTR.

Additional data indicating that neither template-encoding nor noncoding (e.g., regulatory) differences between B6 and CAST/Ei mTR are responsible for loss of elongation came from observations of [(B6 \times CAST/Ei) F1 \times B6] animals. In $mTR^{+/-}$ mice from these crosses, the functional copy of mTR could derive from either parental species. If the species origin of mTR were causing impaired elongation, this would only be seen in 50% of the animals. However, a deficiency in telomere elongation was observed in each of 17 $mTR^{+/-}$ [(B6 $mTR^{+/-}$ \times CAST/Ei) F1 \times B6] mice. These results indicate that genetic polymorphisms linked to the mTR gene are not responsible for impaired telomere elongation observed in $mTR^{+/-}$ mice.

Discussion

A New Telomere Set Point Is Established in Interspecies Crosses. In crosses between *M. musculus* mice with characteristically long telomeres (\approx 50 kb) and SPRET/Ei mice with shorter telomeres (10–15 kb), a dominant mechanism acts to elongate telomeres of SPRET/Ei origin *in vivo* (7). This mechanism establishes a new set point for telomere length in interspecies F1 animals. In the present study, we extended the analysis of interspecies telomere elongation. Crosses of B6 \times CAST/Ei showed a similar elon-




Fig. 3. Telomeres shorten in $mTR^{-/-}$ offspring of crosses between B6 $mTR^{+/-}$ and $mTR^{+/-}$ mice with short telomeres. (A) TRF distributions from B6 $mTR^{+/-}$ and (B6 $mTR^{+/-}$ \times SPRET/Ei) $mTR^{+/-}$ parents and $mTR^{+/+}$, $mTR^{+/-}$, and $mTR^{-/-}$ offspring of a (B6 $mTR^{+/-}$ \times SPRET/Ei) $mTR^{+/-}$ \times B6 $mTR^{+/-}$ cross. End-labeled (CCCTAA)₃ probe was used in in-gel hybridization to *DpnII* digests of agarose-embedded genomic DNA. The boxed region represents the shortest telomeres where differences in the distributions are most evident. (B) TRF distributions from B6 $mTR^{+/-}$ and CAST/Ei $mTR^{+/-}$ parents and $mTR^{+/+}$, $mTR^{+/-}$, and $mTR^{-/-}$ offspring of a B6 $mTR^{+/-}$ \times CAST/Ei $mTR^{+/-}$ cross. CAST/Ei $mTR^{+/-}$ mice used here were bred by backcrossing $mTR^{+/-}$ (B6 \times CAST/Ei) F1 mice three times to CAST/Ei. The boxed region represents the shortest telomeres where difference in the distributions are most evident. (C) Q-FISH analysis of telomeres from $mTR^{+/+}$, $mTR^{+/-}$, and $mTR^{-/-}$ offspring of a [B6 $mTR^{+/-}$ \times (B6 $mTR^{+/-}$ \times SPRET/Ei) $mTR^{+/-}$] cross. Frequency distributions of 2,400 telomere signals from three mice of each genotype are shown.

gation of the short CAST/Ei telomeres in F1 animals. Selective lengthening of short telomeres in interspecies crosses thus seems to be a general phenomenon.




Fig. 4. Similar levels of telomerase activity are expressed in $mTR^{+/+}$ and $mTR^{+/-}$ mice. Lysates were prepared from *in vitro* activated spleen cells derived from age-matched [(B6 $mTR^{+/-}$ \times SPRET/Ei) \times B6 $mTR^{+/-}$] mice that were genotypically $mTR^{+/+}$, $mTR^{+/-}$, or $mTR^{-/-}$ and serially diluted before analyzing telomerase activity. Telomerase activity is shown for 4,000, 2,000, 1,000, and 500 cell equivalents. As a control for telomerase activity, a sample (4,000 cell equivalents) was heated to 85°C for 10 min. IS, the band produced by the internal standard included in the TRAP reaction.

Telomerase RNA Is Limiting in the Establishment of a New Set Point.

To characterize the role of telomerase in elongation of telomeres, we generated interspecies crosses in mice deficient for telomerase. Unexpectedly, we found a deficiency in SPRET/Ei and CAST/Ei telomere elongation to the new interspecies set point in $mTR^{+/-}$ heterozygotes. These results indicate that telomerase is required for elongation to the new set point and that the dose of *mTR* gene has a significant functional effect on telomere elongation. Quantitative analysis of *mTR* levels showed that *mTR* RNA is reduced in $mTR^{+/-}$ mice relative to the level in wild-type $mTR^{+/+}$ mice. There thus exists a dose-response relation between *mTR* expression and functional telomere length maintenance *in vivo*.

The factors that determine telomere elongation *in vivo* are not fully understood. Although both TR and TERT are essential for telomerase activity, it is not known whether telomerase RNA or the catalytic telomerase reverse transcriptase (TERT) is quantitatively limiting *in vivo*. A recent report suggested that *mTERT* is limiting in murine embryonic stem cells because embryonic stem cells that are heterozygous for *mTERT* deficiency undergo accelerated telomere shortening (24). The data presented here suggest that the RNA component may be limiting under certain *in vivo* conditions.

Telomere Function Is Maintained Even with Limiting Telomerase.

To compare the deficiency in elongation in $mTR^{+/-}$ interspecies mice




Fig. 5. mTR RNA levels are reduced in mTR heterozygous mice. Relative RNA concentrations (ng) were calculated from a standard curve generated from wild-type CAST/Ei mice (see *Materials and Methods*) and are indicated for each genotype. mTR levels were 365 in mTR^{+/+} and 118 in mTR^{+/-} mice, and GAPDH levels were 320 in mTR^{+/+} and 280 in mTR^{+/-} mice. Closed circles represent 10 independent threshold cycle values from mTR^{+/-} mice, and the open circle represents the average. Closed squares represent 12 independent threshold cycle values from mTR^{+/+} mice, and the open square represents the average. (A) mTR. (B) GAPDH.

to a situation in which there is complete loss of telomerase function, we backcrossed mTR^{+/-} interspecies mice to B6 mTR^{+/-} mice to generate [(B6 × SPRET/Ei) × B6] and [(B6 × CAST/Ei) × B6] mice with the genotypes mTR^{+/+}, mTR^{+/-}, and mTR^{-/-}. mTR^{+/-} mice showed similar telomere elongation to that seen in mTR^{+/+} (B6 × SPRET/Ei) F1 mice. mTR^{+/-} [(B6 × SPRET/Ei) × B6] and [(B6 × CAST/Ei) × B6] mice had short telomeres that were not different in length from telomeres present in parental SPRET/Ei and CAST/Ei mice, as had been observed in mTR^{+/-} F1 mice. In contrast, mTR^{-/-} mice showed substantial shortening

of the short SPRET/Ei and CAST/Ei-derived telomeres. In all metaphases examined by Q-FISH, TTAGGG sequences were visible on all telomeres in both mTR^{+/-} and mTR^{-/-} mice. In addition, no chromosome fusions were seen in these mice, indicating that telomere function was not compromised by the limiting telomerase. It was notable that, even with limiting telomerase, there were fewer telomeres in the shortest class in mTR^{+/-} mice from [(B6 × SPRET/Ei) × B6] and [(B6 × CAST/Ei) × B6] crosses compared with their mTR^{-/-} littermates. This suggests that telomerase may be specifically recruited to the shortest telomeres even when the telomere set point cannot be maintained. These conclusions are similar to those described for heterozygous mTERT^{+/-} embryonic stem cells. Although both mTERT^{-/-} and mTERT^{+/-} embryonic stem cells show telomere shortening, telomere signal is not lost from the ends of mTERT^{+/-} chromosome, whereas it is lost from mTERT^{-/-} chromosomes (25). Thus, the maintenance of a specific telomere length set point is separable from maintenance of telomere function.

Haploinsufficiency May Cause a Phenotype After a Lag. The recent discovery that the autosomal dominant disease dyskeratosis congenita is due to deletion of one copy of the telomerase RNA gene (15) provides additional evidence for phenotypic consequence of telomerase RNA haploinsufficiency. Although we did not find evidence for loss of telomere function in the first or second generation of heterozygous mice, it is possible that a phenotypic lag in the appearance of telomere dysfunction may occur in these F1 heterozygous mice. This phenotypic lag would resemble that seen for mTR^{-/-} mice (13), but it is likely to occur more slowly. Even though telomerase is targeted to the shortest telomeres, at a certain point the limiting telomerase may not be able to maintain the length of the large number of critically short telomeres. The onset of disease in dyskeratosis congenita patients was reported to occur at progressively younger ages in successive generations, suggesting that such a phenotypic lag in the appearance of consequences of haploinsufficiency may operate in this disease.

We thank Carl Barrett, Lea Harrington, Andre Nussenzweig, Michael Seldin, and Jennifer Hackett for critical reading of this manuscript. We thank Jiunn-liang Chen for advice on PCR cloning and real-time PCR of mTR and Genevieve Sanchez and staff at Bioqual for expert animal care and breeding. K.K.O. was supported by a Leukemia and Lymphoma Society Postdoctoral Fellowship. This work was sponsored in part by National Institutes of Health Grant CA16519 (to C.W.G.).

- Greider, C. W. (1996) *Annu. Rev. Biochem.* **65**, 337–365.
- McEachern, M. J., Krauskopf, A. & Blackburn, E. H. (2000) *Annu. Rev. Genet.* **34**, 331–358.
- Harley, C. B., Futcher, A. B. & Greider, C. W. (1990) *Nature (London)* **345**, 458–460.
- Greider, C. W. & Blackburn, E. H. (1989) *Nature (London)* **337**, 331–337.
- Walmsley, R. M. & Petes, T. D. (1985) *Proc. Natl. Acad. Sci. USA* **82**, 506–510.
- Burr, B., Burr, F. A., Matz, E. C. & Romero-Severson, J. (1992) *Plant Cell* **4**, 953–960.
- Zhu, L., Hathcock, K. S., Hande, P., Lansdorp, P. M., Seldin, M. F. & Hodes, R. J. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 8648–8653.
- Ritchie, K. B., Mallory, J. C. & Petes, T. D. (1999) *Mol. Cell. Biol.* **19**, 6065–6075.
- van Steensel, B. & de Lange, T. (1997) *Nature (London)* **385**, 740–743.
- Shore, D. (1997) *J. Biochem. (Tokyo)* **378**, 591–597.
- Krauskopf, A. & Blackburn, E. H. (1996) *Nature (London)* **383**, 354–357.
- Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A. & Greider, C. W. (1997) *Cell* **91**, 25–34.
- Lee, H.-W., Blasco, M. A., Gottlieb, G. J., Horner, J. W., II, Greider, C. W. & DePinho, R. A. (1998) *Nature (London)* **392**, 569–574.
- Hemann, M. T. & Greider, C. W. (2001) *Mol. Biol. Cell* **12**, 2023–2030.
- Vulliamy, T., Marrone, A., Goldman, F., Dearlove, A., Bessler, M., Mason, P. J. & Dokal, I. (2001) *Nature (London)* **413**, 432–435.
- Hemann, M. T. & Greider, C. W. (2000) *Nucleic Acids Res.* **28**, 4474–4478.
- Lansdorp, P. M., Verwoerd, N. P., van de Rijke, F. M., Dragowska, V., Little, M. T., Dirks, R. W., Raap, A. K. & Tanke, H. J. (1996) *Hum. Mol. Genet.* **5**, 685–691.
- Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L. & Shay, J. W. (1994) *Science* **266**, 2011–2015.
- Hathcock, K. S., Weng, N.-p., Merica, R., Jenkins, M. K. & Hodes, R. J. (1998) *J. Immunol.* **160**, 5702–5706.
- Overbergh, L., Valckx, D., Waer, M. & Mathieu, C. (1998) *Cytokine* **11**, 305–312.
- Kipling, D. & Cooke, H. J. (1990) *Nature (London)* **347**, 400–402.
- Starling, J. A., Maule, J., Hastie, N. D. & Allshire, R. C. (1990) *Nucleic Acids Res.* **18**, 6881–6888.
- Chen, J. L., Blasco, M. A. & Greider, C. W. (2000) *Cell* **100**, 503–514.
- Liu, Y., Snow, B. E., Hande, M. P., Yeung, D., Erdmann, N. J., Wakeham, A., Itie, A., Siderovski, D. P., Lansdorp, P. M., Robinson, M. O. & Harrington, L. (2000) *Curr. Biol.* **10**, 1459–1462.
- Liu, Y., Kha, H., Ungrin, M., Robinson, M. O. & Harrington, L. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 3597–3602.